Literature DB >> 22130964

Selective adenosine agonists and myocardial perfusion imaging.

Gilbert J Zoghbi1, Ami E Iskandrian.   

Abstract

Selective adenosine receptor agonists have several advantages for use as stress agents in conjunction with myocardial perfusion imaging compared to the non selective agents such as adenosine and dipyridamole. This review will summarize the pre-clinical and clinical data on the selective adenosine agonist stress agents regadenoson (Lexiscan(®)), binodenoson (CorVue™) and apadenoson (Stedivaze™) that have been studied so far with focus on regadenoson that has the most clinical data published so far. The article will review the adenosine receptor types and properties. It will also review the various attributes of the selective adenosine agonists including their pharmacology, pharmacokinetics and pharmacodynamics, their coronary vasodilatory and hemodynamic effects, their safety and side effects, their interactions with other drugs and their use with myocardial perfusion imaging. The landmark trials of the selective adenosine agonists will be reviewed as well as their use in special patient populations undergoing stress myocardial perfusion imaging.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22130964     DOI: 10.1007/s12350-011-9474-9

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  39 in total

Review 1.  The role of capillaries in determining coronary blood flow reserve: Implications for stress-induced reversible perfusion defects.

Authors:  S Kaul
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

2.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

3.  Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers.

Authors:  Richard J Barrett; Michael J Lamson; James Johnson; William B Smith
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

4.  Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.

Authors:  Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2010-04-23       Impact factor: 5.952

5.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

6.  Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma.

Authors:  John J Murray; John M Weiler; Lawrence B Schwartz; William W Busse; Rohit K Katial; Richard F Lockey; E R McFadden; Glenn C Pixton; Richard J Barrett
Journal:  Circ Cardiovasc Imaging       Date:  2009-09-17       Impact factor: 7.792

Review 7.  The future of pharmacologic stress: selective A2A adenosine receptor agonists.

Authors:  Manuel D Cerqueira
Journal:  Am J Cardiol       Date:  2004-07-22       Impact factor: 2.778

8.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

9.  Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs.

Authors:  Gong Zhao; Axel Linke; Xiaobin Xu; Manuel Ochoa; Francis Belloni; Luiz Belardinelli; Thomas H Hintze
Journal:  J Pharmacol Exp Ther       Date:  2003-09-03       Impact factor: 4.030

10.  Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus.

Authors:  Fadi G Hage; Jaekyeong Heo; Billy Franks; Luiz Belardinelli; Brent Blackburn; Whedy Wang; Ami E Iskandrian
Journal:  Am Heart J       Date:  2009-03-06       Impact factor: 4.749

View more
  31 in total

1.  The effect of caffeine on adenosine myocardial perfusion imaging: time to reassess?

Authors:  Fadi G Hage; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2012-06       Impact factor: 5.952

2.  When to re-dose regadenoson?

Authors:  Gregory S Thomas; Aaron F Jolly; Michael Safani
Journal:  J Nucl Cardiol       Date:  2015-12-29       Impact factor: 5.952

3.  Vasodilator stress agents for myocardial perfusion imaging.

Authors:  Rayan Saab; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2016-02-02       Impact factor: 5.952

Review 4.  Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.

Authors:  Vasken Dilsizian; Henry Gewirtz; Nicholas Paivanas; Anastasia N Kitsiou; Fadi G Hage; Nathan E Crone; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2015-05-15       Impact factor: 5.952

5.  Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging.

Authors:  Rami Doukky; Adebayo Olusanya; Raj Vashistha; Abhimanyu Saini; Ibtihaj Fughhi; Khaled Mansour; Abiy Nigatu; Kara Confer; Shannon A Sims
Journal:  J Nucl Cardiol       Date:  2015-04-24       Impact factor: 5.952

Review 6.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

7.  Regadenoson-induced complete heart block and asystole: A real possibility nuclear laboratories should be aware of.

Authors:  Faraz Kureshi; Mouin S Abdallah; Timothy M Bateman
Journal:  J Nucl Cardiol       Date:  2016-12-20       Impact factor: 5.952

8.  The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging.

Authors:  Javier Gomez; Yasmeen Golzar; Ibtihaj Fughhi; Adebayo Olusanya; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2017-02-08       Impact factor: 5.952

9.  Use of regadenoson in end-stage renal disease.

Authors:  Ami E Iskandrian; Fadi G Hage; Jaekyeong Heo
Journal:  J Nucl Cardiol       Date:  2013-04       Impact factor: 5.952

Review 10.  Regadenoson: a focused update.

Authors:  Gopal Ghimire; Fadi G Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2013-04       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.